Financiere de Tubize SA
F:FTD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Financiere de Tubize SA
F:FTD
|
BE |
|
L
|
Longfor Group Holdings Ltd
XBER:RLF
|
CN |
|
X
|
Xylem Inc
F:XY6
|
US |
|
A
|
Andean Precious Metals Corp
XTSX:APM
|
CA |
|
Equinox Gold Corp
TSX:EQX
|
CA |
|
Full Truck Alliance Co Ltd
NYSE:YMM
|
CN |
|
V
|
Vesuvius PLC
DUS:V4S
|
UK |
|
Assembly Biosciences Inc
NASDAQ:ASMB
|
US |
|
S
|
Sigdo Koppers SA
SGO:SK
|
CL |
|
Ichor Holdings Ltd
LSE:0Z0F
|
US |
|
S
|
Seven & i Holdings Co Ltd
SWB:S6M
|
JP |
|
S
|
Snap-On Inc
DUS:SPU
|
US |
|
Banco Comercial Portugues SA
OTC:BPCGF
|
PT |
|
MDA Ltd
TSX:MDA
|
CA |
Financiere de Tubize SA
Financiere de Tubize is a Belgian holding company whose main asset is a large stake in UCB, the drugmaker. It does not make medicines itself or run a regular operating business. Instead, it acts as a long-term owner of that shareholding and a way for investors to gain exposure to UCB through a separate listed company. The company’s money comes mainly from dividends and other returns tied to its UCB shares, rather than from selling products or services to customers. Its business is simple: hold the investment, collect the cash that UCB distributes, and manage the ownership structure around that stake. Because of that, its results are closely linked to UCB’s performance and dividend policy. What makes Financiere de Tubize different is that it sits one step above the operating business in the value chain. It is not a pharmaceutical company, but a holding vehicle that gives investors a focused way to own part of a major biopharma group. That makes it more like a concentrated investment company than a traditional industrial or healthcare business.
Financiere de Tubize is a Belgian holding company whose main asset is a large stake in UCB, the drugmaker. It does not make medicines itself or run a regular operating business. Instead, it acts as a long-term owner of that shareholding and a way for investors to gain exposure to UCB through a separate listed company.
The company’s money comes mainly from dividends and other returns tied to its UCB shares, rather than from selling products or services to customers. Its business is simple: hold the investment, collect the cash that UCB distributes, and manage the ownership structure around that stake. Because of that, its results are closely linked to UCB’s performance and dividend policy.
What makes Financiere de Tubize different is that it sits one step above the operating business in the value chain. It is not a pharmaceutical company, but a holding vehicle that gives investors a focused way to own part of a major biopharma group. That makes it more like a concentrated investment company than a traditional industrial or healthcare business.
